We describe the use of a successful combination of Bayesian inference and decision theory in a clinical trial design. The trial involves three important decisions, adaptive dose allocation, optimal stopping of the trial, and the optimal terminal decision upon stopping. For all three decisions we use a formal Bayesian decision-theoretic approach.
3 are known and conditioned upon, d * 2 (d 1 , y 1 ) = arg max u(d, θ, y) p(θ, y 2 | y 1 ) dθ dy 2 . The optimal solution for d 2 is substituted when evaluating the utility for the first stage decision d * 1 = arg max d 1 u(d 1 , d * 2 (d 1 , y 1 ), θ, y) p(θ, y) dθ dy = arg max d 1 y 1 max d 2 θ,y 2 u(d 1 , d 2 , θ, y) p(θ, y 2 | y 1 )dθ dy 2 p(y 1 ) dy 1 . (1) Problems with an alternating sequence of decisions and observations as in (1) are known as sequential decision problems. In general, the solution of sequential decision problems requires computationally intensive backward induction. See, for example, DeGroot (1970) for a description. One important feature of the solution (1) is that strict adherence to the Bayesian decision-theoretic framework requires that all decisions be made with respect to the same utility function. Different decisions only require different choices of conditioning and marginalizations.
The need for formal decision-theoretic approaches for clinical trial planning was highlighted as early as Anscombe (1963) . More recent general discussions appear in Berry (1993 Berry ( , 2004 Berry ( and 2006 , and Spiegelhalter et al. (2004) . In practice, however, unabashedly Bayesian decision-theoretic approaches in clinical trial design are rare. Many Bayesian clinical trial designs use an approach that combines posterior inference for the probability model with reasonable, but ad-hoc rules for the desired decisions. A typical example is Thall et al. (1995) and Yin et al. (2006) who proceed by evaluating posterior probabilities of clinically meaningful events. When these probabilities cross predefined boundaries certain decisions are indicated. The boundaries are set at clinically meaningful values. The design is validated by evaluating frequentist properties. If necessary, boundaries are adjusted to achieve desired frequentist properties, while keeping the value of the boundary within a clinically meaningful range. Such decision rules are referred to as partial Bayes (Berry and Stangl, 1996) or proper Bayes (Spiegelhalter et al., 2004) . They stop short of a decision theoretic framework with utility functions and expected utility maximization.
The following challenges currently prevent Bayesian decision-theoretic approaches from being implemented more widely. But all of them can be overcome in principle and can provide unique opportunities. Prior elicitation for complex probability models, like the model described in this article, poses a difficult challenge. Rather than seeing this challenge as a problem, we argue that it provides an opportunity for early team-building and discussion of critical issues pertinent to the drug development program. Another major challenge is the choice of the utility function. We argue that careful consideration of the appropriate utility function provides a great opportunity to involve health economic aspects early on and move the perspective from thinking about an isolated project, to considering a longer term program, portfolio, or even society at large. A third important challenge involves computational difficulties in implementing expected utility maximization. Carlin et al. (1998) and Brockwell and Kadane (2003) propose simuluation-based implementations of sequential designs. Christen et al. (2004) and Berry and Kadane (1997) justify randomization in a Bayesian decision-theoretic setup by appropriate considerations of the utility function. Stallard (2003) and Rossell et al. (2005) discuss decision-theoretic Bayesian designs that consider multiple studies simultaneously, i.e., designs for a drug development process involving multiple studies.
In this article, we describe a Bayesian decision-theoretic approach to an adaptive design for a dose-finding trial. Central to the decision-theoretic approach is a utility function that formalizes the relative benefits of alternative dose assignments and stopping decisions. For practical reasons we choose to deal separately with the decisions related to dose assignment and to sequential stopping.
We first consider the dose allocation problem. We propose a utility function related to learning about the unknown dose-response curve. Specifically, we use the posterior variance of some key summary statistic of the dose-response curve. The suggested dose for the next patient in the trial is the dose resulting in maximum expected utility. After each patient cohort we consider sequential stopping. We decide whether or not the trial should continue to accrue patients. For this decision we use a utility function that is built on a stylized description of a possibly following confirmatory trial. The utility function includes a large reward for a statistically significant outcome at the end of the future confirmatory trial, and a sampling cost for the future trial. The problem of choosing an appropriate reward for an eventual significant outcome illustrates the challenge of utility elicitation.
For the study discussed in this article we fixed the reward based on elicitation with marketing experts in the company.
The discussion in this article is motivated by a phase II dose-response finding study as conducted in the context of a drug development program of a neuroprotectant for acute stroke. Background of the motivating clinical trial, implementation details and simulation studies to evaluate the performance of the proposed approach in that study are discussed in Berry et al. (2001) . In this article we focus on the underlying decision-theoretic model.
In Section 2, we describe the motivating application. Section 3 introduces the underlying probability model. In Section 4, we develop an approach for optimal dose allocation. In Section 5, we solve the optimal stopping problem. Section 6 concludes with a final discussion.
Data
The motivating case study is a phase II dose-response finding study as conducted in the context of a drug development program of a neuroprotectant for acute stroke. Clinical aspects of the study are described in Krams et al. (2003) and Grieve and Krams (2005) . week M measurements as latent data. We will denote with y ij the measurement on patient i in week j, j = 0, . . . , M . We will use y i without a second index to denote the final outcome y iM . An important covariate is y i0 , the baseline measurement on the clinical outcome of interest at the time of admitting the patient into the study. We will use x i to generically denote the covariate vector.
In the current implementation the only covariate considered is baseline score, i.e., x i = y i0 . Other covariates that might be useful in a stroke trial include time delay between the onset of stroke and the administration of therapy, stroke severity, and indicators for ischemic versus hemorrhagic stroke and cortical versus subcortical stroke. 
Probability Model
The choice of the probability model for f (z) is guided by the following considerations. First, we need a model that allows analytic posterior inference to facilitate efficient computation of expected utilities when solving the decision problem. Second, we want a flexible model which includes a priori a wide range of dose-response curves. Although an increasing curve with asymptotes is a priori likely, the model should allow for possible lack of monotonicity and other irregular features. provide evidence for non-monotonic response-curves of the experimental drug. Based on these considerations we chose a normal dynamic linear model (NDLM). See, for example, West and Harrison (1997) for a formal definition and discussion of NDLM's. Denote with Z j , j = 1, . . . , J, the range of allowable doses, and with θ j = f (Z j ), j = 1, . . . , J, the vector of mean responses at the allowable doses. The underlying idea is to formalize a model which locally, for z close to Z j ,
is the vector of responses y i of all patients with assigned dose z i = Z j . Note the notational convention of using upper case symbols for quantities Z j and Y j indexed by doses, and lower case y i and z i for quantities indexed by patients.
We use an NDLM that assumes Y jk = θ j + jk with the following prior probability model for θ = (θ 1 , . . . , θ J ). The prior specifies that the coefficients change between doses by extrapolating the line and adding an evolution error, θ j+1 = θ j + δ j (Z j − Z j−1 ) + e j1 and δ j+1 = δ j + e j2 . The residual jk and the evolution error e j = (e j1 , e j2 ) are assumed normal distributed, jk ∼ N (0, V σ 2 ) and e j ∼ N (0, W ). The pairs (θ j , δ j ) are known as the state parameters of the NDLM. The model includes the hyperparameters σ 2 , V , W and (θ 0 , δ 0 ). We fix V and W and assume conjugate hyperpriors for θ 0 , δ 0 and σ 2 . The main attraction of the NDLM is the availability of a straightforward recursive algorithm to compute the posterior distribution p(θ | Y 1 , . . . , Y J ) and any other desired posterior inference. The algorithm, known as Forward Filtering Backward Sampling (FFBS), is described in Frühwirt-Schnatter (1994) and Carter and Kohn (1994) . It can be shown that the posterior
Here Y −jk denotes the data with Y jk removed. West and Harrison (1997) give recursive equations to exactly compute the moments of these posterior distributions.
A minor shortcoming of the NDLM in the present application is that the prior specification does not naturally allow one to fix arbitrary desired prior moments for θ j = f (Z j ). Only E(θ 0 ) and V ar(θ 0 ) are fixed. Prior expectation and variance for θ j , j > 0, are then implied by the evolution equation. To increase the number of prior parameters and allow for essentially arbitrary prior moments E(θ j ) and V ar(θ j ) we augment the model by introducing dummy observationsỸ j , Author: Article Short Title Article submitted to Decision Analysis; manuscript no. (Please, provide the mansucript number!) 7 j = 0, . . . , J, with associated observation varianceσ 2 j . When going through the FFBS scheme for posterior inference in the NDLM we proceed then as ifỸ j were data sampled fromỸ j ∼ N (θ j ,σ 2 j ). By appropriate choice ofỸ j andσ 2 j we can achieve any prior moments for θ j , subject only to technical constraints (for example, the marginal prior variances V ar(θ j ) can not be larger than those implied without the dummy observations).
For many patients with missing final score y i we have earlier scores available, y ij , j < M . From historical data we expect y ij , even for j as early as week 4, to be a good predictor of y i . We extend the probability model with a longitudinal data model for (y ij , j = 1, . . . , M ) to allow formal imputation. We assume
Conditional on y ij we assume that y i and any earlier response y ij , j < j, are conditionally independent. This formalizes the notion that knowing the latest available score we should ignore earlier responses. This implies
with parameters m , a and s 2 which are easily derived from m, a and s 2 .
In the following discussion we will use θ = (θ 1 , δ 1 , . . . , θ J , α J , σ 2 , m 1 , a 1 , s 2 1 , . . . , m M , a M , s 2 M ) to denote the vector of all unknown model parameters.
We have introduced the NDLM and (2) as a flexible and computationally convenient probability model for the curve (θ 1 , . . . , θ J ) and the observed outcomes y ij . For the upcoming discussion, the only important feature of the probability model is the availability of computationally easy and fast algorithms to evaluate the posterior mean curve and related posterior probabilities. The proposed approach remains equally valid for any other probability model. Examples of alternative probability models that might be appropriate for other applications are non-linear regression models with a shifted and scaled logistic mean function, spline models, and models with non-normal sampling distributions.
Adaptive Dose Allocation
Based on the assumed probability model, we can now consider the problem of computing an optimal dose for the next patients. Let N denote the number of currently accrued patients, and let K denote the maximum number of patients who are recruited into the trial on one day. Let θ denote the vector of all unknown model parameters. We shall compute the optimal doses to be assigned to the next K patients, i = N + 1, . . . , N + K. The idea is to choose a dose Z j which in expectation will let us learn most about the doseresponse curve f (z, θ), where we write f (z, θ) instead of f (z) to indicate that the dose-response curve is parameterized by θ. Of course a specific implementation requires a formal definition of this vague notion. How should we formalize learning, and with respect to which probability model is the expectation to be taken?
We formalize learning as reducing posterior variance in some key parameters of the dose-response curve. In the current implementation we use as key parameter Z95 θ , the ED95 of the dose-response curve. Here the ED95 is defined as follows. For given parameters θ, let z o θ denote the dose with
In words, the ED95 dose Z95 θ is the minimum dose for which the dose response curve f (z, θ)
achieves at least 95% of the maximum possible improvement.
For a formal description of the optimal dose finding, letỹ = (ỹ 1 , . . . ,ỹ K ) = (y N +1 , . . . , y N +K ) =, k = 1, . . . , K denote the (still unknown) responses of the future patients with covariatesx = (x 1 , . . . ,x K ) = (x N +1 , . . . , x N +K ). Letz k denote the -to be determined -dose for the future patient N + k. Let D denote the already observed data on previous patients, including early responses for patients with still missing final response, and letD denote the missing final responses for previous patients. Let g(θ) denote the key parameter, for example g(θ) = Z95 θ . We consider posterior variance of g(θ) to define a utility function for the choice of the optimal dosez k :
whereḡ = g(θ) dp(θ | D,D,ỹ 1 , . . . ,ỹ k ) denotes the posterior mean. Note that u k does not (yet) depend on the actionz k . The dependence onz k will be introduced when we take the expectation with respect to the responseỹ k . Matching the notation in (3) with the notation for the generic Bayesian decision problem in the introduction, note that (D,D,ỹ 1 ,x 1 , . . . ,ỹ k ,x k ) are all observable random quantities, and u k does in this case not include the parameters θ or the actionz k . In other words, the definition of u k already includes the integration with respect to θ.
Of course we have to choose dosage for the future patients before observing (x,ỹ,D). Thus choice ofz k is based on averaging u k (·) with respect to the relevant posterior predictive distribution on (D,ỹ 1 , . . . ,ỹ k ), and with respect to a distribution p(x) onx 1 , . . . ,x k−1 , derived from historical data. Forx k we substitute covariates x 0 of a "typical" patient, i.e., we compute the optimal dose allocation for a typical patient. Reporting a patient-specific recommended dose that depends on Author: Article Short Title Article submitted to Decision Analysis; manuscript no. (Please, provide the mansucript number!) 9 the baseline covariatex k would create excessive logistical difficulties for the administration of this multi-center trial.
Here U k (z j ) is the expected utility of decisionz k = Z j for a future patient, i.e., U k (z j ) expresses how much deciding on dose Z j is worth to us. See below for the distribution p(x) and the assumed doses forz 1 , . . . ,z k−1 . The solution to the optimal dose problem is then formalized as
In words, recommend the dose which in expectation maximizes the utility defined by expected posterior variance on the key parameters g(θ). The expectation is with respect to responses y N +k
and covariates x N +h of future patients h = 1, . . . , k (exceptx k ), and with respect to still missing final responses y i of current patients, i = 1, . . . , N .
For a practical implementation of the proposed optimal design approach it is critical that the posterior variance integral in (3) and the expected utility integral (4) be available for efficient evaluation, analytically or by numerical integration. One of the reasons for choosing the NDLM model was that the posterior variance of the response at the ED95, the choice for g(θ) in our implementation, can be evaluated analytically. See the appendix for a description of a detailed algorithm based on the commonly used recursive equations to compute posterior moments for the state parameters.
However, the expected utility integral (4) is not analytically tractable. Instead we used independent Monte Carlo simulation. First we generate by computer simulation posterior samples from p(θ | D), using the FFBS algorithm; andx h ∼ p(x h ), h = 1, . . . , k − 1, using the empirical distribution from a historical data base of patients treated for the same medical condition. For each patient h = 1, . . . , k − 1 we then substitute the optimal dosez h that we found earlier by maximizing U h , h = 1, . . . , k − 1. Based on these imputed values for θ andx h and the assigned dosesz h , h = 1, . . . , k − 1, we can generate the missing data valuesD andỹ 1 , . . . ,ỹ k−1 . Given these simulations we evaluate the posterior variance u k (D,D,ỹ 1 ,x 1 , . . . ,ỹ k ,x k ). Repeating the same simulation many times, say M times, we can replace the integral (4) by a sample average over the evaluated posterior variances. Note that the criterion (4) is myopic in the sense that we only think ahead for the next K patients. Also, the choice of the posterior variance of Z95 θ as a formal definition of learning about the curve is arbitrary. Possible alternatives are to consider posterior variance on more than one key parameter, or some measure of information gain, like Kulback-Liebler divergence of prior and posterior. The small signal to noise ratio is realistic for the reported response. Figure 2b shows the estimated expected utility curve U (Z j ), defined in (4) Figure 2c shows a trace of assigned doses over the course of the entire simulated trial. Note how the system correctly narrows in around Z j = 1.0. The ED95 in the true dose-response curve that was used to simulate the data is at 1.0.
The utility function (3) focuses on the learning about the curve. In other applications, alternative and additional goals might be of interest. For example, one might want to add a term related to the outcomesỹ 1 , . . . ,ỹ k . Technically, any expression that can be evaluated for an assumed set of decisions, future outcomes and hypothetical parameter values could be used. We recommend that the utility function should include a reward for learning about the unknown curve. However, the focus need not be exclusively on this goal. Other terms can be added to the utilty function without changing the proposed approach. indicating termination with the recommendation to abandon the drug (stopping for futility), d t = 1
Optimal Stopping
indicating continuation, and d t = 2 indicating termination with the recommendation to initiate a confirmatory phase III study that compares the drug at the recommended dose against placebo (stopping for efficacy). The recommended dose is the currently estimated ED95, E(Z95 θ | D t ).
We assume that the confirmatory trial is set up as a three-arm trial comparing placebo (z = 0), recommended dose z = E(Z95 θ | D t ), and z = E(Z50 θ | D t ). The third arm is included as an alternative dose. The data D t to compute the posterior expectation is the data at the time of stopping, i.e., when d t = 2. Let df = f (z , θ) − f (0, θ) denote the advantage over placebo at the recommended dose, and let (m t , s t ) denote the posterior mean and standard deviation of df (again, conditional on D t ). We assume that at the conclusion of the pivotal trial a hypothesis test is carried out to compare H 0 : df = 0 versus H 1 : df > 0, using an approximately normal distributed zstatistic to compare the two treatment arms z = 0 and z = z . Let D P denote the observed responses in the future pivotal trial, let n P denote the number of patients enrolled in the future pivotal trial.
We assume that the sample size n P for the pivotal trial is chosen to achieve 90% Bayesian power.
Bayesian power is calculated using a normal approximation to the posterior predictive distribution 12 Article submitted to Decision Analysis; manuscript no. (Please, provide the mansucript number!) p(df | D t ). See, for example, Spiegelhalter et al. (2004, chapter 6.5 .3) for a discussion of Bayesian power. Briefly, it is the probability of rejecting the null hypothesis, taking the expectation with respect to (in this case) the joint posterior predictive distribution of df and D P given D t . We write n P (D t ) to highlight the nature of n P as a function of the data. Alternative sample size calculations could be used. In particular, one could use traditional (frequentist) power instead of Bayesian power. Also, as usual in sample size arguments, the target of 90% is a reasonable but arbitrary choice. Any alternative threshold could be used without changing the approach, if desired.
The evaluation of alternative actions d t requires us to compare the sampling cost for a possible future pivotal trial, and weight it against the benefit of a significant outcome of the pivotal trial, weighted by the appropriate probability of such an outcome. If we decide to continue, d t = 1, then we need to consider the cost of one more patient cohort and the optimal decision in the next period. A utility function that formalizes these aspects allows us to formally compare the alternative actions. Let B(D P ) denote the event of finding at the conclusion of the pivotal trial a statistically significant advantage over placebo, and let m P = E(df | D t , D P ) denote the estimated effect at the recommended dose z . Let K denote the expected number of accrued patients in the time interval between t and t + 1. We use the utility function
In words, if we decide to terminate the trial and abandon the experimental therapy, no further loss or payoff occurs. If we decide to stop and move to the pivotal trial, we incur a fixed cost c 0 to set up the study, and the sampling cost (c 1 per patient) for the pivotal trial. A major payoff (c 2 m P ) is awarded if the trial concludes with a statistically significant effect of the new therapy. The payoff is proportional to the estimated effect, with c 2 specified as payoff per point advantage over placebo.
If we decide to continue, then we pay the sampling cost for the next cohort of patients, and get the optimal reward in the next period. The outer expectation, in the second line of (5), is with respect to all patients who are enrolled between time t and t + 1. The inner expectation is with respect to all other future outcomes that are required in the evaluation of u(d t+1 , D t+1 , D P ), including in particular the future pivotal trial data.
The evaluation of the utility of continuation, d t = 1, requires the optimal solution for the stopping decision d t+1 in the next period. This characterizes a sequential decision problem, as in (1), and greatly complicates the solution of the decision problem. Maximizing the expected utility function to find the optimal decision is a computationally challenging problem. A full solution involves
Author: Article Short Title Article submitted to Decision Analysis; manuscript no. (Please, provide the mansucript number!) 13 the use of backward induction. See, for example, DeGroot (1970) . Instead we use a simulationbased approximate solution, based on the method proposed in Brockwell and Kadane (2003) and Müller et al. (1999) . First we restrict the decision d t (D t ) to depend on the data only indirectly through (m t , s t ). Recall that (m t , s t ) were defined as the posterior moments of df . We consider a bivariate grid on (m t , s t ). Let U
with summaries (m t , s t ) ≈ (m, s) with (m, s) being the closest values on the (m t , s t ) grid. We use Monte Carlo integration to evaluate the expectation U G (d, m, s) . Carlin et al. (1998) refer to this strategy as forward simulation. There remains the problem that the evaluation of U G (d = 1, m, s) requires to substitute the optimal decision for the next period. We solve this by using an iterative algorithm. We start out with initial values for all fields U G (d, m, Similar to (3), the choice of (5) is arbitrary. We believe that the proposed utility is a reasonable stylized description of the drug developer's goals. An alternative choice could, for example, include the treatment success for future patients who will benefit from a successful drug development.
Or one could consider minor changes, such as replacing the estimated advantage over placebo E(df | D t , D P ) by the true advantage over placebo, df .
Discussion
We proposed a Bayesian decision-theoretic approach to a phase II dose-response finding study. For the adaptive dose allocation we use a utility function which formalizes learning about the unknown dose-response curve. We showed how the required computations become practically feasible when using an appropriate probability model for the dose-response curve and, if necessary, for the longitudinal model of delayed responses. For the sequential stopping decision we used a utility function that involves a reward for a statistically significant outcome of a subsequent pivotal trial.
The discussed implementation includes several compromises with a strict decision-theoretic textbook approach. First, we used several utility functions for the different decisions. In a strict implementation of the paradigm of expected utility maximization one would state only one utility function, and all decisions would be made with respect to that utility function. Also, in the discussion of the adaptive dose allocation we ignored the sequential aspect of the problem.
Implementation of the proposed approach involved several, to some level arbitrary, decisions to formalize general concepts. For example, many alternatives exist to the chosen specification for the Author: Article Short Title Article submitted to Decision Analysis; manuscript no. (Please, provide the mansucript number!) 15 utility function (3). Also, the probability model could be modified in several directions without compromising the overall goal of achieving a computationally feasible framework for a decisiontheoretic optimal solution to the given design problem. For example, the NDLM could include additional covariates (in the observation equation); we could choose alternative NDLM models which specify different levels of smoothing; the longitudinal data model could include a regression on the baseline score y i0 , etc.
We discussed in some detail the two important decisions related to the dose allocation for the next patients and optimal stopping to decide continuation of the trial. Carrying out the trial requires a loop over alternating steps that invoke the two decisions. Practical implementation also needs an elaborate system to make the data available for the continuous updating of posterior and posterior predictive distributions. For multicenter trials this is not a trivial effort. We used an automated fax system in the study underlying the discussion of this paper.
Before the trial is initiated the same system is used in a simulation mode, that is, with simulated patient responses in place of actual data, to evaluate frequentist operating characteristics under selected scenarios. Frequentist operating characteristics are summaries of the system performance under a specific assumed true dose-response curve. Summaries are evaluated as averages over repeated simulations of possible patient outcomes, keeping the assumed fixed truth. Such summaries are traditional criteria to evaluate and critique clinical trial designs.
Bayesian clinical trial design is not a panacea. It only provides a framework for a principled approach to the development of study designs. Actual implementation usually requires extensive consideration and judgement to specify the sampling models, the prior distributions, the utility functions, and finally to find practicable implementations. The rewards for the effort are manifold. A good Bayesian study design will allow early stopping for futility and will indicate when an expansion of the originally planned sample size is called for. The sequential stopping rule presented here is one way of achieving this flexibility. Another important advantage of a model based Bayesian decision-theoretic approach is that there always is a gold standard, namely the Bayes rule that is defined by the expected utility optimization. A practical implementation often calls for approximations and simplifications. But these choices are always guided by the theoretically optimal solution. One of the practically important aspects of Bayesian inference is the ease of hiearchical modeling. Most studies include some notions of hierarchical structure. Examples are different patient subpopulations defined by, e.g., biomarkers, treatment history, family history, or treatment centers; different treatments; different treatment schedules; multiple cycles of treatment;
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